Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRP203 in moderately active refractory ulcerative colitis
NCT01375179Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of mocravimod in ulcerative colitis (UC), sponsored by Novartis. Primary endpoint: Change in clinical remission rate at 8 weeks. Started Dec 2010; status: terminated.
02
Drugs
mocravimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01375179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01375179.